A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation (NCT07217067)
A Randomized, Placebo-controlled, Participant- and Investigator-blinded Study to Evaluate the Efficacy in Reducing Atrial Fibrillation Burden (AFB) as Well as the Safety, Tolerability, and Pharmacokinetics of Oral PKN605 in Participants With Atrial Fibrillation
🩺 Plain-English Summary (8th-Grade Level)
A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation
Who can join: Review the eligibility criteria below.
Location: Cardiology Associates of North MS — Tupelo, Mississippi
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (40 Sites)
Showing the first 25 of 40 sites.
- Cardiology Associates of North MS — Tupelo, Mississippi
- Cooper University Hospital — Camden, New Jersey
- Weill Cornell Medical Center — New York, New York
- Duke Univ Medical Center — Durham, North Carolina
- Intermountain Medical Center — Murray, Utah
- Swedish Heart and Vascular Clinic — Seattle, Washington
- Novartis Investigative Site — Calgary, Alberta
- Novartis Investigative Site — Vancouver, British Columbia
- Novartis Investigative Site — Halifax, Nova Scotia
- Novartis Investigative Site — Hamilton, Ontario
- Novartis Investigative Site — London, Ontario
- Novartis Investigative Site — Newmarket, Ontario
- Novartis Investigative Site — Toronto, Ontario
- Novartis Investigative Site — Toronto, Ontario
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Québec, Quebec
- Novartis Investigative Site — Sherbrooke, Quebec
- Novartis Investigative Site — Beijing, Beijing Municipality
- Novartis Investigative Site — Beijing,
- Novartis Investigative Site — Xi'an,
- Novartis Investigative Site — Bad Homburg,
- Novartis Investigative Site — Berlin,
- Novartis Investigative Site — Berlin,
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atrial Fibrillation
- CHAMPION-AF Clinical Trial — Birmingham, Alabama
- Reversal of Atrial Substrate to Prevent Atrial — Calgary, Alberta
- Insertable Cardiac Monitor for Primary Atrial Fibrillation Detection in High-Risk Heart Failure Patients — Rochester, New York
- REView of ProcEdural FactoRs and Outcomes After Atrial Fibrillation Ablation With Active Esophageal COOLing: A Sub-Study of the REAL AF Registry — Chandler, Arizona
- Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF) — Cleveland, Ohio
- Liraglutide Effect in Atrial Fibrillation — Miami, Florida
Explore by condition: All Atrial Fibrillation clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.